Literature DB >> 2999195

Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.

J R Sainsbury, A J Malcolm, D R Appleton, J R Farndon, A L Harris.   

Abstract

Epidermal growth factor receptors are present in some breast cancers in man, and there is an inverse relation to oestrogen receptor state. We assessed the presence of epidermal growth factor receptors as a single prognostic indicator in a series of breast tumours by comparing this with the Bloom and Richardson scores for these tumours. One hundred and eight ductal tumours were examined for epidermal growth factor receptors by radioligand binding. There was a significant (p less than 0.01) correlation between the presence of the growth factor receptor and poor prognosis as assessed by the Bloom and Richardson score, suggesting that epidermal growth factor receptor state could be a useful prognostic marker. Epidermal growth factor receptor state was not significantly correlated with the lymph node state but showed a tendency to be associated with large tumours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999195      PMCID: PMC499417          DOI: 10.1136/jcp.38.11.1225

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Functional EGF receptors are present on mouse embryo tissues.

Authors:  E D Adamson; M J Deller; J B Warshaw
Journal:  Nature       Date:  1981-06-25       Impact factor: 49.962

2.  Receptor binding and processing of epidermal growth factor by human breast cancer cells.

Authors:  C K Osborene; B Hamilton; M Nover
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

3.  Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.

Authors:  J F Stewart; R J King; S A Sexton; R R Millis; R D Rubens; J L Hayward
Journal:  Eur J Cancer       Date:  1981-04       Impact factor: 9.162

4.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

5.  Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture.

Authors:  Y Imai; C K Leung; H G Friesen; R P Shiu
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

6.  Epidermal growth factor requirement for development of cultured mammary gland.

Authors:  Q J Tonelli; S Sorof
Journal:  Nature       Date:  1980-05-22       Impact factor: 49.962

7.  Expression of epidermal growth factor receptors in human brain tumors.

Authors:  T A Libermann; N Razon; A D Bartal; Y Yarden; J Schlessinger; H Soreq
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Biological action of epidermal growth factor and its functional receptors in normal mammary epithelial cells.

Authors:  Y Taketani; T Oka
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

9.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  39 in total

1.  Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line.

Authors:  Yong He; Jun Zhou; Jin-Sheng Wu; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 2.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  Epidermal growth factor receptor on human thyroid neoplasms.

Authors:  H Masuda; A Sugenoya; S Kobayashi; Y Kasuga; F Iida
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

4.  Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast.

Authors:  P Möller; G Mechtersheimer; M Kaufmann; G Moldenhauer; F Momburg; T Mattfeldt; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  Quality control of oestrogen receptor assays using frozen breast tumours.

Authors:  S Y Wong; G King; B Angus; A Tesdale; R A Hawkins
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

6.  Epidermal growth factor receptors and prognosis in primary breast cancer.

Authors:  F Spyratos; J C Delarue; C Andrieu; R Lidereau; M H Champème; K Hacène; M Brunet
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

7.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

Authors:  X Wu; Z Fan; H Masui; N Rosen; J Mendelsohn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 8.  Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.

Authors:  A E Wakeling; A J Barker; D H Davies; D S Brown; L R Green; S A Cartlidge; J R Woodburn
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors.

Authors:  C Charpin; B Devictor; P Bonnier; L Andrac; M N Lavaut; C Allasia; L Piana
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  The prognostic significance of epidermal growth factor receptor expression in breast cancer.

Authors:  M Noguchi; Y Mizukami; K Kinoshita; M Earashi; M Thomas; I Miyazaki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.